This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Masoprocal

Insmed, Inc.

Drug Names(s): INSM-18

Description: INSM-18 is a small molecule tyrosine kinase inhibitor that has demonstrated selective inhibition of the insulin-like growth factor-I receptor (IGF-I) and human epidermal growth factor receptor (Her2/neu). It has demonstrated anti-tumor activity in preclinical studies of breast, lung, pancreatic and prostate tumors.

Deal Structure: In January 2007, Insmed entered into an agreement with NAPO Pharmaceuticals, whereby NAPO will license from us the technology surrounding INSM-18 also known as Masoprocal. The license gives NAPO the right to develop, manufacture and commercialize Masoprocal products for any indications relating specifically to diabetes, cardiac disease, vascular disease, metabolic disease and Syndrome X. The agreement calls for payments from NAPO to us upon the delivery of certain milestones.

In December 2010, Insmed entered into an agreement with TriAct Therapeutics Inc., whereby TriAct obtained an exclusive license from Insmed for INSM-18 also known as Masoprocal. The license gives TriAct the right to develop, manufacture and commercialize Masoprocal products for any indications relating specifically to Oncology. The agreement calls for the issue of TriAct common stock to Insmed upon the achievement of certain milestones. As of March 2011, no common stock has been received.

Partners: Triact Therapeutics, Inc. Napo Pharmaceuticals, Inc.


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug